The skeletal-related events of denosumab versus zoledronic acid in patients with bone metastases: A meta-analysis of randomized controlled trials
Conclusion Denosumab was more effective than ZA in reducing the incidence of SRE in patients with bone metastases.
Source: Journal of Bone Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | China Health | Conferences | Databases & Libraries | Orthopaedics | Reclast | Science | Study | Xgeva | Zometa